跳至主要内容
临床试验/CTRI/2024/07/070555
CTRI/2024/07/070555尚未招募不适用

An Open Label, prospective, Randomized, Placebo Controlled, Three-Treatment, Parallel, Comparative Trial to determine the safety, efficacy and ease of use of Transdermal Application of Multi Nutrient lotion manufactured by Murlikrishna Pharma Pvt. Ltd., India with standard Supportive Care Treatment infemale patients with mild Anemia

Murali Krishna Pharma Pvt Ltd1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2024年7月22日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
300
试验地点
1
主要终点
300 study participants - To evaluate the efficacy of transdermal application of Multi nutrient Lotion for prevention of micronutrient deficiencies in mildly anemic women

研究概览

简要总结

STUDY TITLE: “A
Triple-Blind, Prospective, Randomized, Placebo-Controlled, Three-Treatment, Parallel, Comparative Trial
to determine the safety,
efficacy and ease of use of
Transdermal Application of Multi Nutrient Lotion manufactured by Murlikrishna Pharma
Pvt. Ltd., India
with Standard Supportive Care Treatment in  female patients with mild
Anemia”.
Protocol No.

VRL-CT-23-020

|Version No.

1.0

|Date

22 Sep 2023

|Principal Investigator

Dr. Hema Divakar

 Screening period

After obtaining the informed consent, patients will be screened by undergoing various assessments as mentioned in Schedule of Assessment. The total duration of study   will be of 12 weeks, which excludes 3 week (maximum) of screening period.

The study consists of following visits:

·         Visit 1 (Day -21 to -1): Screening period

·         Visit 2 (Day 1): Randomization visit

·         Visit 3 (Day 28 ± 2 Day) (Week 4): Treatment visit

·         Visit 4 (Day 56 ± 2 Day) (Week 8): Treatment visit

·         Visit 5 (Day 84 ± 2 Day) (Week 12): End of Study visit

 Eligible patients will be given either:

 Arm A: Transdermal Liposomal Lotion of each 2.5 ml Contains Ferrous Bisglycinate (Elemental Iron 5 mg), Vitamin B12 (0.0004 mg), Vitamin D3 (0.01 mg) & Folic Acid (0.05 mg) 5ml single application once a day on the skin over the dorsum aspect of either forearm, preferably at same time daily for the entire study duration

 Arm B: Ferrous bisGlycinate (Elemental Iron 30 mg), Zinc picolinate (Elemental Zinc 11 mg), Folic acid (0.5 mg) & Vitamin B12 (7.5 mcg) Tablets – one table orally once daily preferably at same time daily for the entire study duration

Arm C: Placebo Transdermal Liposomal Lotion

  • 5ml single application once a day on the skin over the dorsum aspect of either forearm, preferably at same time daily for the entire study duration

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 50.00 Year(s)(—)
性别
Female

入选标准

  • Subjects meeting following criteria will be included in the study:
  • Female patients with age 18-50 years (both inclusive), residing in the study area.
  • Iron deficiency anemia with low hemoglobin ranging from 9-10.9 g/dL at the onset of the study (at first visit).
  • Patient is willing to give informed consent, able to provide availability for the entire study period and follow study protocol.

排除标准

  • Women or girls with significant co-morbidities including hemoglobinopathies.
  • Patients who have received blood or blood products transfusion during the current illness
  • Patients with generalized skin disorder hampering the regular application transdermal of investigational drug
  • Pregnant and lactating women.

结局指标

主要结局

300 study participants - To evaluate the efficacy of transdermal application of Multi nutrient Lotion for prevention of micronutrient deficiencies in mildly anemic women

时间窗: (Day 84 ± 2 Day) (Week 12)

次要结局

  • To evaluate the safety & tolerability of transdermal application of Multi nutrient Lotion for prevention of micronutrient deficiencies in mildly anemic women. Time points One year.(One year)

研究者

发起方
Murali Krishna Pharma Pvt Ltd
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Hema Divakar

Medical Director - Divakars Speciality Hospital

研究点 (1)

Loading locations...

相似试验